Sibel Health, known for its innovative contributions to the digital health sector, has completed a Series C extension financing round. This latest funding effort adds a layer of support to the company, bringing its total Series C funding to an impressive $39 million. The extension attracted several strategic investors, including Maruho and Samsung Next. This follows the initial Series C round, which was concluded earlier this year with leadership from The Steele Foundation for Hope, complemented by significant investments from Dräger.
Maruho is a prominent player in Asia’s dermatological products market, specializing in the development and commercialization of skin-related health solutions. Their investment in Sibel Health further solidifies an already established commercial partnership focused on creating innovative therapeutic digital health technologies specifically for dermatology. This collaboration promises to enhance the effectiveness and accessibility of treatment options in this vital area of healthcare.
Sibel Health’s cornerstone product, the FDA-cleared clinical monitoring platform known as ANNE One, effectively leverages Samsung mobile devices for its waveform display and alerting capabilities. This integration not only enhances the platform’s usability but also showcases the potential for synergy between Sibel’s technology and Samsung’s mobile innovations.
In addition to the funding announcement, Sibel Health is strengthening its leadership team with two significant board appointments to guide the company through its next phase of growth. Kimberly Querrey, the Chair and CEO of Gulf Shore Private Capital, LLC, has been elected Chairwoman of the board. Querrey has been involved with Sibel Health since its inception in 2018 and brings extensive experience as a Trustee of Northwestern University, where she plays an active role on the Executive Committee and chairs the Nominations and Governance Committee.
Additionally, Sibel Health announced the recruitment of Tim Sullivan as a new independent board member. Sullivan is not only a Co-Founder and Vice Chair of Madison Dearborn Partners but also serves as Chairman of the Board of Northwestern Memorial Healthcare Corporation. His background and insights into innovation, healthcare, and commercial acceleration will be invaluable as Sibel Health continues to expand its reach and impact in the digital health landscape.
Together, these developments position Sibel Health for significant advancements in its mission to improve patient care through leading-edge technology and strategic partnerships.
KEY QUOTES:
“These new partners bring more than capital — they bring unique expertise, scale, and reach for our clinical-grade medical wearables and AI-driven algorithms.”
“From Maruho’s deep pharmaceutical and dermatology experience and Samsung Next’s global technology and innovation ecosystem, each of these new partners plays a critical role in advancing our vision of a future where continuous, real-world health data is seamlessly integrated into clinical trials and clinical care. With a deeply experienced board, we are well positioned to accelerate the transition from episodic reactive monitoring to continuous and predictive clinical intelligence with our products.”
Dr. Steve Xu MD, CEO of Sibel Health
“We are excited to partner with Sibel Health as we co-develop future digital health breakthroughs for skin conditions globally starting first with itch.”
Akihiko Ikoma MD PhD, Senior Medical Director, Maruho Co., Ltd.
“I look forward to leveraging my 30 years of experience in business operations, corporate governance, and board leadership to guide the CEO and Sibel Health on its exciting trajectory.”
Kimberly Querrey
“Care is moving far beyond the four walls of the hospital — and we are excited to illustrate this with a growing number of hospital partners. At Samsung Next, we see strong potential in Sibel’s best-in-class medical wearables paired with Samsung mobile devices. Together, they could create a differentiated product for healthcare providers and life science companies that’s both clinically validated and cost-effective.”
Jonathan Machado, Managing Director at Samsung Next
